nash – Page 4 – Scalper1

GenFit NASH Data Drives Up Rival Intercept

Biotech Intercept Pharmaceuticals (ICPT) spiked more than 9% to near 285 Thursday afternoon when a competitor’s clinical trial produced ambiguous results. GenFit, a French biotech that doesn’t trade in the U.S., announced that its drug GFT505 had failed to meet its primary endpoint in non-alcoholic steatohepatitis (NASH), a form of liver damage caused by accumulation of fat. Progress was measured by performing a liver biopsy at the beginning and

Gilead Acquires Drug Program For Fatty Liver Disease

Big-cap biotech Gilead Sciences (GILD) agreed Tuesday to acquire a program from small German biotech Phenex Pharmaceuticals aimed at treating liver disease. Gilead agreed to an unspecified upfront payment and milestone payments totaling up to $470 million for Phenex’s Farnesoid X Receptor program. The company press release emphasized that one of the targets of this program is non-alcoholic steatohepatitis (NASH), a common but largely untreated